The 5-HT2-serotonin and D2-dopamine families of receptors represent essential targets for most atypical antipsychotics as well as drugs useful in treating obesity, sleep disorders, psychosis and autistic-spectrum disorders. It is currently unknown how these drugs interact with their target receptors. Here we aim to obtain high resolution structures of 5-HT2A- and 5-HT2B- serotonin and D2- and D4-dopamine receptors with an array of small molecules. These studies are both innovative technically and conceptually by providing an unprecedented understanding of the molecular and atomic details responsible for psychoactive drug actions. Technical achievements will include the structure of LSD in complex with its key serotonin receptor targets and typical and atypical antipsychotic drugs in complex with their serotonin and dopamine receptor targets. Additionally, models which attempt to explain ligand-specific properties of biased signaling from the perspective of ligand-receptor interactions will be tested by a combination of direct structural studies, molecular modeling, docking, site-directed mutagenesis and functional studies. We anticipate that our studies will reveal key ligand-receptor interactions essential for biased signaling for serotonin and dopamine receptors. Elucidating the molecular details for such interactions provides a template for the structure-guided design of novel therapeutics.
Roth, Bryan L PROJECT NARRATIVE (RELEVANCE) The design of new drugs to treat major mental disorders remains challenging and error-prone. This grant seeks to discover how drugs used for treating mental disorders bind to an modulate the activity of their receptor sites of action. Such information could be used to accelerate the discovery of new treatments for serious mental disorders such as schizophrenia and depression. OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015) Page Continuation Format Page
| Wang, Sheng; Che, Tao; Levit, Anat et al. (2018) Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 555:269-273 |
| McCorvy, John D; Butler, Kyle V; Kelly, Brendan et al. (2018) Structure-inspired design of ?-arrestin-biased ligands for aminergic GPCRs. Nat Chem Biol 14:126-134 |
| Peng, Yao; McCorvy, John D; Harpsøe, Kasper et al. (2018) 5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. Cell 172:719-730.e14 |
| Ishchenko, Andrii; Wacker, Daniel; Kapoor, Mili et al. (2017) Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody. Proc Natl Acad Sci U S A 114:8223-8228 |
| Wang, Sheng; Wacker, Daniel; Levit, Anat et al. (2017) D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358:381-386 |
| Wacker, Daniel; Wang, Sheng; McCorvy, John D et al. (2017) Crystal Structure of an LSD-Bound Human Serotonin Receptor. Cell 168:377-389.e12 |
| Wacker, Daniel; Stevens, Raymond C; Roth, Bryan L (2017) How Ligands Illuminate GPCR Molecular Pharmacology. Cell 170:414-427 |
